Completed PHASE3 INTERVENTIONAL 2-arm NCT03216473

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of NEURONOX® vs. BOTOX® in Patients With Essential Blepharospasm

Sponsor: Medy-Tox

Conditions Essential Blepharospasm

Interventions Botox Neuronox

Updated 4 times since 2017 Last updated: Jul 12, 2017 Started: May 25, 2016 Primary completion: Mar 17, 2017 Completion: Jul 4, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03216473, this PHASE3 trial focuses on Essential Blepharospasm and remains completed. Sponsored by Medy-Tox, it has been updated 4 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medy-Tox

Data source: Medy-Tox

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.